Basilea Pharmaceutica AG Stock
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
03:30:30 31/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 70.80 CHF | -0.98% |
|
+3.36% | +29.43% |
| 27/10 | Basilea Pharmaceutica Lifts FY26 Guidance | MT |
| 27/10 | Basilea raises full-year guidance 2026 and financial target for "Agenda 2030" and provides updates on late-stage clinical programs | DJ |
| Market Cap | 879M 1.07B 956M 797M 1.49B 101B 1.52B 10.49B 4.21B 53.32B 4.01B 3.92B 168B | P/E 2026 * |
14.4x | P/E 2027 * | 16.2x |
|---|---|---|---|---|---|
| Enterprise Value | 722M 877M 785M 654M 1.22B 83.24B 1.25B 8.61B 3.46B 43.78B 3.29B 3.22B 138B | EV / Sales 2026 * |
2.64x | EV / Sales 2027 * | 2.25x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
CBOE
| 0QNA | Real-time | |
|
London S.E.
| 0QNA | Delayed | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
OTC Markets
| BPMU.F | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Xetra
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -0.98% | ||
| 1 week | +3.36% | ||
| Current month | +1.29% | ||
| 1 month | +1.29% | ||
| 3 months | +35.63% | ||
| 6 months | +30.15% | ||
| Current year | +29.43% |
| 1 week | 68.7 |  | 75.8 |
| 1 month | 64.1 | | 75.8 |
| Current year | 47.8 | | 75.8 |
| 1 year | 44.7 | | 75.8 |
| 3 years | 32 | | 75.8 |
| 5 years | 29.55 | | 75.8 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/5/26 | Sell | -400 | 0.0030% | |||
| 13/5/26 | Sell | -1,043 | 0.0078% | |||
| 4/5/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.98% | +3.36% | +53.08% | +97.77% | 1.07B | |
| -0.62% | -1.87% | +46.31% | +56.99% | 64.38B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.16B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.16B | |
| -2.81% | -4.31% | +23.50% | +50.90% | 45.33B | |
| -0.33% | -1.93% | +20.15% | +98.45% | 42.25B | |
| +0.55% | +2.31% | +224.97% | +942.56% | 40.78B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 33.8B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.25B | |
| -1.29% | -2.88% | +21.60% | -11.92% | 23.57B | |
| Average | -0.01% | +4.48% | +54.75% | +156.97% | 39.38B | |
| Weighted average by Cap. | +0.02% | +3.54% | +52.31% | +161.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 273M 332M 297M 248M 463M 31.5B 472M 3.26B 1.31B 16.57B 1.25B 1.22B 52.26B | 294M 357M 320M 267M 498M 33.91B 508M 3.51B 1.41B 17.84B 1.34B 1.31B 56.26B |
| Net income | 68.15M 82.72M 74.09M 61.75M 115M 7.85B 118M 813M 326M 4.13B 310M 304M 13.03B | 61.7M 74.9M 67.08M 55.91M 105M 7.11B 106M 736M 295M 3.74B 281M 275M 11.8B |
| Net Debt | -157M -191M -171M -142M -266M -18.12B -271M -1.87B -753M -9.53B -716M -701M -30.06B | -217M -264M -236M -197M -368M -25.05B -375M -2.59B -1.04B -13.18B -990M -969M -41.56B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | CHF 70.80 | -0.98% | 33,532 |
| 29/10/26 | CHF 71.50 | -2.59% | 25,484 |
| 28/10/26 | CHF 73.40 | +1.66% | 40,184 |
| 27/10/26 | CHF 72.20 | +4.79% | 151,426 |
| 26/10/26 | CHF 68.90 | +0.58% | 15,982 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
